Compare Becton Dickinson and Co (BDX) vs Lamb Weston Holdings Inc (LW) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Becton Dickinson and Co vs Lamb Weston Holdings Inc — how do they compare? Becton Dickinson and Co trades at $154.29 (market cap $41.51B), while Lamb Weston Holdings Inc trades at $46.3 (market cap $6.42B). The key difference: Becton Dickinson and Co is far larger — about 6.5× Lamb Weston Holdings Inc's market cap, and Lamb Weston Holdings Inc pays the higher dividend (3.27%). Which is the better fit depends on your goals.
| BDX | LW | |
|---|---|---|
Market Cap | $41.51B | $6.42B |
Sector | Health | Consumer Staples |
52-Week High | $185.39 | $66.57 |
52-Week Low | $135.49 | $38.48 |
Enterprise Value | $57.97B | $10.38B |
Dividend Yield | 2.79% | 3.27% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BDX trades at $153.83, up 1.24% today, with technical indicators showing a neutral to bullish bias. The company has consistently beaten earnings estimates in recent quarters, with Q1 2026 EPS of $2.90 exceeding expectations. Revenue growth remains steady, reaching $21.84B in 2025, though net margins have compressed to 5.12%. Recent news highlights BDX's innovation in medical technology and positive analyst sentiment.
The outlook for BDX appears balanced. Upside potential exists from continued earnings beats and strategic positioning in growing healthcare segments like GLP-1 drug support equipment. However, risks include margin pressure, elevated debt levels, and cautious hospital spending. The consensus price target of $173.40 suggests moderate upside from current levels.
Lamb Weston (LW) trades at $46.98, up 1.14% with a bullish technical signal and consistent earnings beats. The company shows strong operational cash flow of $868.3M in 2025 and maintains positive revenue growth, though net income margin declined to 4.61%. Recent news highlights the 'Focus to Win' strategy showing early traction with North America volume gains and cost savings.
Outlook remains cautiously optimistic with analyst consensus price target of $49.33 offering 5% upside. Key risks include ongoing securities litigation and margin pressure from competitive dynamics. Institutional sentiment leans positive with activist involvement signaling potential value creation opportunities.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Becton Dickinson and Co
Becton, Dickinson is the world's largest manufacturer and distributor of medical surgical products, such as needles, syringes, and sharps-disposal units. The company also manufactures diagnostic instruments and reagents, as well as flow cytometry and cell-imaging systems. BD Interventional (largely the former Bard business) accounts for 23% of revenue. International revenue accounts for 44% of the company's business.
Read more on BDX →About Lamb Weston Holdings Inc
Lamb Weston is the world's second-largest producer of branded and private-label frozen potato products, such as French fries, sweet potato fries, tater tots, diced potatoes, mashed potatoes, hash browns, and chips. The company also has a small appetizer business that produces onion rings, mozzarella sticks, and cheese curds. Including joint ventures, 63% of fiscal 2022 revenue was U.S.-based, with the remainder stemming from Europe, Canada, Japan, China, Korea, Mexico, and several other countries. Lamb Weston's customer mix is estimated 58% quick-serve restaurants, 19% full-service restaurants, 8% other food services (hotels, commercial cafeterias, arenas, schools), and 16% retail. Lamb Weston became an independent company in 2016 when it was spun off from Conagra.
Read more on LW →
